Having trouble accessing articles? Reset your cache.

Latent Value Finds a Home

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc. The newco was set up expressly to develop the preclinical assets by way of venture financing and/or partnership.

ZymoGenetics last week granted Seattle Life Sciences exclusive worldwide rights to eight programs, including three mAbs

Read the full 685 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers